Close Menu

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said today that it has signed a research agreement with Spain's Instituto Valenciano de Oncología (IVO) to develop and validate a breast cancer recurrence risk score using the company's technology.

Under the terms of the deal, the partners will use HTG's EdgeSeq Oncology biomarker panel to develop a breast cancer recurrence risk score based on genes differentially expressed in patients with low and high risk of recurrence. Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.